Sintilimab and chemo for advanced squamous NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination therapy for people with advanced squamous non-small cell lung cancer. It adds sintilimab (an immunotherapy) and rh-endostatin (a drug that blocks blood supply to tumors) to standard chemotherapy, hoping to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic squamous non-small cell lung cancer (stage IIIB, IIIC, or IV) without certain gene changes.
- You must be between 18 and 70 years old.
- You must not have had previous cancer treatment, or if you had chemotherapy after surgery, the cancer must have returned at least 6 months later.
- You need to be in reasonably good health (able to do daily activities, with no major organ problems).
- You must not have certain autoimmune diseases, heart conditions, bleeding risks, or active infections like hepatitis B, C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Hear when a new Squamous Non-Small Cell Lung Cancer SqNSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.